[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 216,930
  • Shares Outstanding, K 74,291
  • Annual Sales, $ 0 K
  • Annual Income, $ -104,080 K
  • EBIT $ -122 M
  • EBITDA $ -117 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.68

Options Overview Details

View History
  • Implied Volatility 123.47% (+3.83%)
  • Historical Volatility 95.81%
  • IV Percentile 64%
  • IV Rank 12.19%
  • IV High 562.39% on 12/16/25
  • IV Low 62.51% on 01/16/26
  • Expected Move (DTE 18) 0.54 (19.22%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,205
  • Volume Avg (30-Day) 500
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 11,352
  • Open Int (30-Day) 9,864
  • Expected Range 2.29 to 3.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 3
  • High Estimate $-0.34
  • Low Estimate $-0.42
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +9.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +44.39%
on 03/30/26
3.65 -22.47%
on 04/21/26
+0.77 (+37.38%)
since 03/27/26
3-Month
1.91 +48.17%
on 02/05/26
3.65 -22.47%
on 04/21/26
+0.29 (+11.42%)
since 01/27/26
52-Week
1.63 +73.62%
on 07/01/25
3.65 -22.47%
on 04/21/26
+0.72 (+34.12%)
since 04/25/25

Most Recent Stories

More News
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 ...

NKTX : 2.83 (-3.08%)
Nkarta to Participate in Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.83 (-3.08%)
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation...

NKTX : 2.83 (-3.08%)
Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.83 (-3.08%)
Nkarta to Participate in Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.83 (-3.08%)
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights 

Enrollment now underway in second dose-escalation cohort  Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide...

NKTX : 2.83 (-3.08%)
Nkarta to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 2.83 (-3.08%)
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.83 (-3.08%)
Nkarta to Participate in a September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 2.83 (-3.08%)
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected...

NKTX : 2.83 (-3.08%)

Business Summary

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 3.34
2nd Resistance Point 3.21
1st Resistance Point 3.02
Last Price 2.83
1st Support Level 2.70
2nd Support Level 2.57
3rd Support Level 2.38

See More

52-Week High 3.65
Fibonacci 61.8% 2.88
Last Price 2.83
Fibonacci 50% 2.64
Fibonacci 38.2% 2.40
52-Week Low 1.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.